Biosimilar adalimumab for patients with active rheumatoid arthritis
76
0
2023-11-10 16:12
GRacE | The Lancet Group for Racial Equity
The future of medical research
GRacE | The Lancet Group for Racial Equity (BSL-interpreted)
The Carbon Cost of Healthcare (BSL-interpreted)
DAY IN THE LIFE OF A DOCTOR: Rheumatology Rotation
Progressive descending facial nerve paralysis in amyloidosis
Fragile X-associated tremor or ataxia syndrome
Metaphyseal sclerosis in a child with a giant cell tumour treated with denosumab
0 bullet chats
Please Sign In first
LikesSend-PenFavorites
Scan by WeChatUnauthorized reproduction is prohibited
Dr. Roy Fleischmann from the University of Texas Southwestern Medical Center in Dallas, Texas, presents a study of multiple switches between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis.
The study was published in The Lancet Rheumatology in August 2023.
Comments 0
Please to post a comment~
Loading...
Related Suggestion